Bio-Thera Launches Adalimumab In China
Qletli Biosimilar Is First Chinese Humira Rival
Bio-Thera Solutions has launched its first product in China, with its Qletli adalimumab biosimilar representing the first Humira rival to be approved under the country’s biosimilars pathway and just the second biosimilar approved overall.
